HGHmeds Brings Safety and Efficiency to the Expanding Global HGH Market
The Mexico-based hormone clinic, which has online capabilities is doing its part to meet increased global demand for affordable Human...
Year: 2025
PharmaCord Announces Appointment of Robert Truckenmiller as CEO
JEFFERSONVILLE, INDIANA / ACCESS Newswire / January 21, 2025 / PharmaCord LLC, a leading provider of patient services for the...
PharmaCord Announces Appointment of Robert Truckenmiller as CEO
JEFFERSONVILLE, INDIANA / ACCESS Newswire / January 21, 2025 / PharmaCord LLC, a leading provider of patient services for the...
The 2025 Black Book of Behavioral Health IT Released: A Competitive Intelligence Report
Free to participants in the 2025 survey of BHIT software, this comprehensive report offers critical insights into trends, developments, and...
The 2025 Black Book of Behavioral Health IT Released: A Competitive Intelligence Report
Free to participants in the 2025 survey of BHIT software, this comprehensive report offers critical insights into trends, developments, and...
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company...
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters...
Yerbae Expands Midwest Convenience Store Presence with Casey’s General Stores Authorization
SCOTTSDALE, Ariz., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a...
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis...
Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC
PALO ALTO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating...
Heidi Kling: Transforming Mental Health Care Through Advocacy and Action
NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / In an era where mental health challenges continue...
Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa
FORT WORTH, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis...
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
Olympia Pharmaceuticals Expands into Alabama with New Licensing, Bringing GLP-1s and More to Healthcare Providers
Nation’s leading compound pharmacy is now available in 48 statesORLANDO, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals, a...
Welcoming Victor Bornsztejn as Senior Vice President of Commercial
SAN FRANCISCO, CALIFORNIA, UNITED STATES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Culture Biosciences, a leader in cloud-connected bioprocessing technologies, is...
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development...
Completion of Offering and Increase in Registered Capital
TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”), a health technology...
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
- Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track...
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE)...
Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta
Breakthrough Therapy Designation is designed to expedite the development and review of therapies that may show significant improvement over available treatments for...